Are patients on Oral chemotherapy in your practice setting safe?

Clinical Journal of Oncology Nursing

Volumn 14, Issue 3, 2010, Pages 339-346

  Moody, Mendy ^a   Jackowski, Joyce ^b  

^a Rex Hematology/Oncology Associates   (United States)

^b Fairfax Northern Virginia Hematology Oncology PC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; HUMAN; NEOPLASM; NURSE ATTITUDE; NURSING; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NURSE'S ROLE; PATIENT EDUCATION AS TOPIC;

EID: 77956212376     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/10.CJON.339-346     Document Type: Article

References (14)

1. Barefoot, J., Blecher, C.S., & Emery, R. (2009). Keeping pace with oral chemotherapy. Oncology Issues, May/June, 36-39. Retrieved from http://accc-cancer.org/oncology_issues/articles/mayjune09/MJ09-Barefoot.pdf
2. Bartel, S.B. (2007). Safe practices and financial considerations in using oral chemotherapeutic agents. American Journal of Health-System Pharmacy, 64(9, Suppl. 5), S8-S14. doi: 10.2146/ajhp070036
3. Birner, A. (2003). Safe administration of oral chemotherapy. Clinical Journal of Oncology Nursing, 7, 158-162. doi: 10.1188/03.CJON.158-162
4. Bowers, M.L., Silberman, G., & Mortenson, L.E. (2002). Oral oncology products: Barriers to successful adoption. Oncology Issues, 17(1), 26-27.
5. Cassidy, J., Douillard, J.Y., Twelves, C., McKendrick, J.J., Scheithauer, W., Bustova, I., Garrison, L.P. (2006). Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: The X-ACT trial. British Journal of Cancer, 94, 1122-1129. doi: 10.1038/sj.bjc.6603059
6. Genentech, Inc. (n.d.). Xeloda® (capecitabine). Retrieved from http://www.xeloda.com
7. Griffin, E. (2003). Safety considerations and safe handling of oral chemotherapy agents. Clinical Journal of Oncology Nursing, 7(6, Suppl.), 25-29. doi: 10.1188/03.CJON.S6.25-29
8. Hartigan, K. (2003). Patient education: The cornerstone of successful oral chemotherapy treatment. Clinical Journal of Oncology Nursing, 7(6, Suppl.), 21-24. doi: 10.1188/03.CJON.S6.21-24
9. Labuhn, K., Valanis, B., Schoeny, R., Loveday, K., & Vollmer, W.M. (1998). Nurses' and pharmacists' exposure to antineoplastic drugs: Findings from industrial hygiene scans and mutagenicity tests. Cancer Nursing, 21, 79-89.
10. Mayor, S. (2003). UK introduces measures to reduce errors with methotrexate. BMJ, 327, 70.
11. Moore, S. (2007). Facilitating oral chemotherapy treatment and compliance through patient/family-focused education. Cancer Nursing, 30(2), 112-121. doi: 10.1097/01.NCC.0000265009.33053.2d
12. Thomas, F.W., Cahill, A.G., Mortenson, L.E., & Schoenfeldt, M. (2000). Oral chemotherapy, cytostatic and supportive care agents: New opportunities and challenges. Oncology Issues, 15(2), 23-25.
13. Weingart, S.N., Brown, E., Bach, P.B., Eng, K., Johnson, S.A., Kuzel, T.M., Walters, R.S. (2008). National Comprehensive Cancer Network task force report: Oral chemotherapy. Journal of the National Comprehensive Cancer Network, 6(Suppl. 3), S1-S14.
14. Wilkinson, K. (2003). Reimbursement and patient assistance programs for oral chemotherapy agents. Clinical Journal of Oncology Nursing, 7(6, Suppl.), 31-36. doi: 10.1188/03.CJON.S6.31-36